Figure 6. EX enhances the therapeutic efficacy of ABT-737 in a murine model of human AML.
(A) At 5 weeks after i.v. injection of 2.5 × 106 GFP/luciferase-bearing MOLM13 cells, nude mice were sacrificed, and their spleens were analyzed by immunohistochemistry for GFP+ cells. Scale bars: 100 μm (left); 50 μm (right). (B and C) Nude mice xenotransplanted as in A were randomized and treated with control liposomes, ABT-737 liposomes, EX, or EX plus ABT-737, and leukemia burden was noninvasively analyzed as described in Methods. (D) Survival was estimated by Kaplan and Meier analysis as described in Methods. The EX plus ABT-737 treatment group was significantly different from the control (P < 0.005) and ABT-737 alone (P < 0.05) groups.